



September 18, 2017

## **Intra-Cellular Therapies to Participate at Upcoming Investor Conferences**

NEW YORK, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced it will participate at the following investor conferences in September 2017:

- | Cantor Fitzgerald Global Healthcare Conference taking place in New York City from September 25-27, 2017. Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present on Monday, September 25, 2017 at 1:15 pm ET.
- | Ladenburg Thalmann 2017 Healthcare Conference taking place in New York City on September 26, 2017. Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present on Tuesday, September 26, 2017 at 11:00 am ET.

The live and archived webcasts can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at [www.intracellulartherapies.com](http://www.intracellulartherapies.com). Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

### **About Intra-Cellular Therapies**

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company's PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with Parkinson's disease.

### **Contact:**

Juan Sanchez, M.D.  
Vice President  
Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc.  
Phone: 212-923-3344

Burns McClellan, Inc.  
Lisa Burns  
Justin Jackson (Media)  
[jjackson@burnsmc.com](mailto:jjackson@burnsmc.com)  
212-213-0006